

Christopher Grainge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5537816/publications.pdf>

Version: 2024-02-01

56
papers

2,658
citations

257101

24
h-index

189595

50
g-index

58
all docs

58
docs citations

58
times ranked

3754
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarker signatures for progressive idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2022, 59, 2101181.	3.1	30
2	TLR7 agonist loaded airway epithelial targeting nanoparticles stimulate innate immunity and suppress viral replication in human bronchial epithelial cells. <i>International Journal of Pharmaceutics</i> , 2022, 617, 121586.	2.6	1
3	Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 883-891.	2.5	29
4	Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings. <i>Internal Medicine Journal</i> , 2021, 51, 169-180.	0.5	5
5	Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*. <i>Respirology</i> , 2021, 26, 23-51.	1.3	45
6	Cryobiopsy for Identification of Usual Interstitial Pneumonia and Other Interstitial Lung Disease Features. Further Lessons from COLDICE, a Prospective Multicenter Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1306-1313.	2.5	32
7	Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2715-2724.e5.	2.0	15
8	Benefits of a virtual interstitial lung disease <sc>multidisciplinary</sc> meeting in the face of <sc>COVID</sc>-19. <i>Respirology</i> , 2021, 26, 612-615.	1.3	12
9	Dysregulated actin cytoskeleton associated with barrier dysfunction in asthma. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
10	Parapneumonic Effusions Are Characterized by Elevated Levels of Neutrophil Extracellular Traps. <i>Chest</i> , 2021, 160, 1645-1655.	0.4	6
11	A cGAS-dependent response links DNA damage and senescence in alveolar epithelial cells: a potential drug target in IPF. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L859-L871.	1.3	17
12	A Senescence Bystander Effect in Human Lung Fibroblasts. <i>Biomedicines</i> , 2021, 9, 1162.	1.4	12
13	In Reply. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1326-1327.	1.2	1
14	TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001127.	1.2	13
15	Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 171-181.	5.2	253
16	Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database. <i>BMC Pulmonary Medicine</i> , 2020, 20, 257.	0.8	9
17	Methodologies of COLDICE and Cryo-PID studies: details make the difference. <i>Annals of Translational Medicine</i> , 2020, 8, 781-781.	0.7	1
18	Mepolizumab effectiveness and identification of super-responders in severe asthma. <i>European Respiratory Journal</i> , 2020, 55, 1902420.	3.1	124

#	ARTICLE	IF	CITATIONS
19	Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1562-1573.	1.5	35
20	Epithelial Mesenchymal Transition in Respiratory Disease. <i>Chest</i> , 2020, 157, 1591-1596.	0.4	18
21	Airway epithelial-targeted nanoparticles for asthma therapy. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L500-L509.	1.3	23
22	Senescence of IPF Lung Fibroblasts Disrupt Alveolar Epithelial Cell Proliferation and Promote Migration in Wound Healing. <i>Pharmaceutics</i> , 2020, 12, 389.	2.0	30
23	Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner. <i>Clinical Science</i> , 2020, 134, 889-905.	1.8	28
24	The Emerging Role of Neutrophil Extracellular Traps in Respiratory Disease. <i>Chest</i> , 2019, 156, 774-782.	0.4	133
25	Peering deeper into asthmatic lungs. <i>Respirology</i> , 2019, 24, 1037-1038.	1.3	0
26	Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. <i>BMC Pulmonary Medicine</i> , 2019, 19, 84.	0.8	26
27	Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. <i>Respirology</i> , 2019, 24, 988-995.	1.3	7
28	STAT3 Regulates the Onset of Oxidant-induced Senescence in Lung Fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 61, 61-73.	1.4	52
29	Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. <i>Respirology</i> , 2019, 24, 361-368.	1.3	24
30	Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000443.	1.2	17
31	The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 97, 108-117.	1.2	49
32	The effect of inhaled corticosteroids on bone mineral density measured by quantitative ultrasonography in an older population. <i>Clinical Respiratory Journal</i> , 2018, 12, 659-665.	0.6	4
33	Mitochondrial dysfunction contributes to the senescent phenotype of <sc>IPF</sc> lung fibroblasts. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5847-5861.	1.6	65
34	Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. <i>Medical Journal of Australia</i> , 2018, 208, 82-88.	0.8	13
35	Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 315, L162-L172.	1.3	114
36	Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. <i>BMC Pulmonary Medicine</i> , 2018, 18, 19.	0.8	58

#	ARTICLE	IF	CITATIONS
37	Inflammatory insights into airway remodelling in asthma. <i>Respirology</i> , 2018, 23, 1084-1085.	1.3	6
38	Thoracic ultrasound recognition of competence: A position paper of the Thoracic Society of Australia and New Zealand. <i>Respirology</i> , 2017, 22, 405-408.	1.3	34
39	Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. <i>European Respiratory Journal</i> , 2017, 49, 1601592.	3.1	174
40	Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 312, L772-L782.	1.3	30
41	Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017, 50, 1700168.	3.1	32
42	Treatment of idiopathic pulmonary fibrosis in <sc>A</sc>ustralia and <sc>N</sc>ew Zealand: <sc>A</sc>ustralia and <sc>N</sc>ew <sc>Z</sc>ealand and the <sc>L</sc>ung <sc>F</sc>oundation <sc>A</sc>ustralia. <i>Respirology</i> , 2017, 22, 1436-1458.	1.3	39
43	Targeted therapeutics for severe refractory asthma: monoclonal antibodies. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 927-941.	1.3	28
44	Airway Surfactant Protein D Deficiency in Adults With Severe Asthma. <i>Chest</i> , 2016, 149, 1165-1172.	0.4	52
45	IL-1 β mediates cellular cross-talk in the airway epithelial mesenchymal trophic unit. <i>Tissue Barriers</i> , 2016, 4, e1206378.	1.6	16
46	Response. <i>Chest</i> , 2016, 150, 474.	0.4	0
47	Toll-like Receptor 7 Is Reduced in Severe Asthma and Linked to an Altered MicroRNA Profile. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 26-37.	2.5	55
48	Chronic granulomatous disease presenting as refractory pneumonia in late adulthood. <i>Respirology Case Reports</i> , 2015, 3, 54-56.	0.3	9
49	Clinical assessment of speech correlates well with lung function during induced bronchoconstriction. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15006.	1.1	6
50	Asthmatic and Normal Respiratory Epithelial Cells Respond Differently to Mechanical Apical Stress. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 477-480.	2.5	21
51	Potentially Pathogenic Airway Bacteria and Neutrophilic Inflammation in Treatment Resistant Severe Asthma. <i>PLoS ONE</i> , 2014, 9, e100645.	1.1	258
52	Case series reporting the effectiveness of mycophenolate mofetil in treatment-resistant asthma. <i>European Respiratory Journal</i> , 2013, 42, 1134-1137.	3.1	5
53	Epithelial Injury and Repair in Airways Diseases. <i>Chest</i> , 2013, 144, 1906-1912.	0.4	75
54	Resistin-like molecule β is induced following bronchoconstriction of asthmatic airways. <i>Respirology</i> , 2012, 17, 1094-1100.	1.3	15

#	ARTICLE	IF	CITATIONS
55	Effect of Bronchoconstriction on Airway Remodeling in Asthma. New England Journal of Medicine, 2011, 364, 2006-2015.	13.9	491
56	Repeated high-dose inhalation allergen challenge in asthma. Clinical Respiratory Journal, 2011, 5, 150-155.	0.6	10